Novartis to acquire dry eye drug lifitegrast

The prescription dry eye treatment lifitegrast (Xiidra) will change hands from Takeda to Novartis later this year, at an estimated cost of $5.3 billion.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553